Hybrid Vaccine Of Dendritic Cells And Hepatocarcinoma And Its Antitumor Effect In Vivo

Objective to develop vaccine by fusion of H22 hepatocarcinoma cell and DC ,and study its protective and therapeutical effect on H22 cell.Method H22-DC vaccine are produced by PEG fusion of H22 andDC induced by cytokine of spleen mononuclear cell ,sorted by CDllcmagnetic microbead marker.to study the H22-DConcogenesis,pathologically check the organs of liver,spleen and lung afterH22-DC injection from tail vein; for studying H22-DC therapeutical andprotective effect on tumor H22, two groups are divided : immune group andtherapeutic group.immune group are divided to P,H,D and HD subgroups,immunized by PBS,inactivated H22,DC and H22-DC respectively,andattacked by H22 cell, the tumor size,tumor weight , mouse survival periodand tumor latent period are recorded and statisticallyanalysized ;therapeutical group is divided into three subgroups of P,D andHD, and attacked by H22,then therapied by PBS,DC,and H22-DCrespectively. Pathological method and flow cytometry are also applied tostudy the H22JDC vaccine how to kill the H22 cell.Result 1. No oncogenesis in spleen,lung and liver after H22-DC injection; 2.1n immune group, latent period is longer in HD subgroup than in P,H and D subgroup; and tumor size and tumor weight are smaller in HD subgroup than in P,H and D subgroup; 3.In therapeutic group, tumor size is smaller in HD subgroup than in P,D subgroup.4. Flow cytometry shows higher peak of sub-diploid cells in HD than in other subgroups.Conclusion 1. H22-DC vaccine is safe without oncogenesis in vivo;2. H22-DC vaccine has distinctive protective effect on tumor H22 and can inhabit the tumor growth . 3. H22-DC can induce necrosis of H22 cell.